Advanced search
Publication Cover
Current Medical Research and Opinion Volume 38, 2022 - Issue 12
Submit an article Journal homepage
169
Views
1
CrossRef citations to date
0
Altmetric
Oncology

Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR

Christian Geßnera POIS-Leipzig GbR Geßner u. Geßner, Leipzig, Germany
,
Thomas Fietzb Outpatient Center for Hematology, Oncology and Gastroenterology, Singen, Germany
,
Christoph Losemc Outpatient Center for Hematology and Oncology, Neuss, Germany
,
Andreas Lückd Outpatient Center for Urology and Oncology, Rostock, Germany
,
Holger Schulze Outpatient Center for Internal Oncology and Hematology, Frechen, Germany
,
Beate Niemeierf iOMEDICO, Freiburg im Breisgau, Germany
,
Matthias Groschekg Outpatient Center for Hematology and Oncology, Stolberg, Germany
,
Henning Eschenburgh Outpatient Center for Internal Medicine, Hematology and Oncology, Güstrow, Germany
,
Rudolf Weidei Outpatient Center for Hematology and Oncology, Koblenz, Germany
,
Albrecht Kretzschmarj Outpatient Center for Internal Medicine, Hematology and Oncology, Leipzig, Germany
,
Nikolaj Frostk Department of Infectious Diseases and Pulmonary Medicine, Charité-Universitätsmedizin, Berlin, Germany
,
Joachim Hippl Teva GmbH, Ulm, Germany
,
Johanna Hardef iOMEDICO, Freiburg im Breisgau, Germany
,
Christiane D. Matillonf iOMEDICO, Freiburg im Breisgau, Germany
,
Sina Grebhardtf iOMEDICO, Freiburg im Breisgau, Germany
&
Karin Potthofff iOMEDICO, Freiburg im Breisgau, GermanyCorrespondence[email protected]
 show all
Pages 2191-2199 | Received 17 May 2022, Accepted 10 Aug 2022, Published online: 01 Sep 2022

References

  • Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228–237.
  • Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–199.
  • Becker PS, Griffiths EA, Alwan LM, et al. NCCN guidelines insights: hematopoietic growth factors, version 1.2020. J Natl Compr Canc Netw. 2020;18(1):12–22.
  • Aapro MS, Bohlius J, Cameron DA, et al. 2010 Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
  • Cooper KL, Madan J, Whyte S, et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.
  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Supportive Therapie bei onkologischen PatientInnen- Langversion 1.3, 2020. AWMF Registernummer: 032/0540L, https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/. (Zugriff am 19.06.2020) [Internet]. [cited 2020 Jun 19]. Available from: https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Supportivtherapie/LL_Supportiv_Langversion_1.3.pdf.
  • Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(Suppl 5):v111–v118.
  • Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline update. J Clin Oncol. 2015;33(28):3199–3212.
  • Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin’s lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma. 2001;2(1):47–56.
  • Volovat C, Bondarenko IM, Gladkov OA, et al. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. SpringerPlus. 2015;4(1):4.
  • Volovat C, Bondarenko I, Gladkov O, et al. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. Support Care Cancer. 2016;24(12):4913–4920.
  • Bondarenko I, Gladkov OA, Elsaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer. 2013;13:386.
  • Lonquex – Summary of Product Characteristics (SPC) – (eMC) [Internet]. [cited 2017 Sep 19]. Available from: https://www.medicines.org.uk/emc/medicine/28948.
  • Fietz T, Lück A, Schulz H, et al. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR. Curr Med Res Opin. 2019;35(7):1127–1138.
  • Wolff T, Schulz H, Losem C, et al. Prophylaxis of chemotherapy‐induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non‐Hodgkin lymphoma (NADIR study. Eur J Haematol. 2019;102(2):174–181.
  • Common Terminology Criteria for Adverse Events (CTCAE) – CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf [Internet]. [cited 2017 Sep 20]. Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
  • Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996;17(4):343–346.
  • Pichler P, Claes N, Mazza P, et al. Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study. Ann Oncol. 2016;27(Suppl 6):1459P.
  • Steger G, Pichler P, Airoldi M, et al. Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: pan-European non-interventional study. Ann Oncol. 2018;29(suppl_8):viii607–viii608.
  • Fontaine C, Claes N, Graas M-P, et al. Effect of lipegfilgrastim administration as prophylaxis of chemotherapy-induced neutropenia on dose modification and incidence of neutropenic events: real-world evidence from a non-interventional study in Belgium and Luxembourg. Acta Clin Belg. 2021;76(1):10–15.
  • Timmer-Bonte JNH, Ouwerkerk J, Faber LM, et al. Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients. Neth J Med. 2020;78(5):270–276.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.